Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bruker (BRKRP) Capital Expenditures (2016 - 2025)

Bruker's Capital Expenditures history spans 16 years, with the latest figure at $22.6 million for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 38.42% year-over-year to $22.6 million; the TTM value through Dec 2025 reached $90.8 million, down 21.25%, while the annual FY2025 figure was $90.8 million, 21.25% down from the prior year.
  • Capital Expenditures reached $22.6 million in Q4 2025 per BRKRP's latest filing, up from $20.9 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $57.7 million in Q3 2022 to a low of $16.3 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $26.7 million, with a median of $24.6 million recorded in 2021.
  • Peak YoY movement for Capital Expenditures: soared 253.99% in 2022, then crashed 53.38% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $28.4 million in 2021, then increased by 21.83% to $34.6 million in 2022, then fell by 8.96% to $31.5 million in 2023, then grew by 16.51% to $36.7 million in 2024, then crashed by 38.42% to $22.6 million in 2025.
  • Per Business Quant, the three most recent readings for BRKRP's Capital Expenditures are $22.6 million (Q4 2025), $20.9 million (Q3 2025), and $21.3 million (Q2 2025).